SANGAMO THERAPEUTICS, INC
SGMOQ evidence brief
What we can confirm
- BioSniper Score:
- 4.2 / 10
- Market Cap:
- $66.3M
- Cash Runway:
- 4.3 mo
What it means
What to watch
Prepared research question
What matters most for SGMOQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGMOQ
SANGAMO THERAPEUTICS is a genomic medicine company focused on epigenetic regulation therapies for serious neurological diseases, but faces an acute liquidity crisis that threatens its ability to continue operations beyond the third quarter of 2026.
Key risk: Imminent cash depletion
BioSniper Score
Based on 5 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates · 8 clinical trials for SANGAMO THERAPEUTICS, INC.
SANGAMO THERAPEUTICS is a genomic medicine company focused on epigenetic regulation therapies for serious neurological diseases, but faces an acute liquidity crisis that threatens its ability to continue operations beyond the third quarter of 2026.
- Cash and equivalents were $27.6M as of 2026-03-31, with total revenue of $1.4M and a net loss of -$31.0M for the period [sec].
- The company's core preclinical neurology programs include ST-503 for small fiber neuropathy (SFN) and ST-506 for prion disease, both using zinc finger epigenetic regulators delivered via proprietary AAV capsids [sec_mda · as of 2026-05-14].
- ST-503 has received FDA Fast Track Designation and six Phase 1/2 clinical sites are active with patient recruitment underway [sec_mda · as of 2026-03-30].
- The Fabry disease gene therapy candidate isaralgagene civaparvovec (ST-920) has completed a registrational Phase 1/2 study, with a BLA rolling submission expected as early as summer 2026, contingent on securing additional funding [sec_mda · as of 2026-05-14].
- The company has warned it may be forced to cease operations, liquidate assets, or seek bankruptcy protection in the very near term if it cannot secure additional capital [sec_mda · as of 2026-05-14].
What works
- Sangamo has a proprietary zinc finger epigenetic regulation platform and a novel neurotropic AAV capsid (STAC-BBB) that may enable delivery to the central nervous system, which has attracted multiple license agreements with partners such as Genentech, Astellas, and Lilly [sec_mda · as of 2026-03-30].
- The company's wholly owned neurology pipeline has advanced to clinical trials: ST-503 for SFN is in Phase 1/2 with Fast Track Designation, and ST-506 for prion disease has completed GLP toxicology studies and aligned with the UK MHRA on key development steps [sec_mda · as of 2026-05-14].
- Sangamo's Fabry disease gene therapy program has a clear regulatory pathway to Accelerated Approval from the FDA, and the company has begun a rolling BLA submission for isaralgagene civaparvovec [sec_mda · as of 2026-03-30].
What to weigh
- Sangamo's cash runway is critically short; the company states it cannot fund operations beyond the third quarter of 2026 without securing significant upfront funding from collaborations or transactions for its advanced clinical-stage programs [sec_mda · as of 2026-05-14].
- The company has negative shareholders' equity of -$19.0M as of 2026-03-31, indicating that liabilities exceed assets [sec].
- Sangamo has repeatedly reduced headcount and is actively considering further cost-cutting measures, including delaying or discontinuing R&D activities, and has warned it may need to seek bankruptcy protection [sec_mda · as of 2026-03-30].
- The company's stock price has been volatile, and it faces the risk of delisting from Nasdaq, which would further impair its ability to raise capital [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
Sangamo may be forced to cease operations or seek bankruptcy protection in the very near term.
“to or may be required to cease operations entirely, liquidate all or a portion of our assets, and/or seek protection under the U.S. Bankruptcy Code in the very near term, and you may lose all or part of your investment.”
SEC MD&A · May 14, 2026
Cash runway extends only to the third quarter of 2026.
“our ability to fund our current operations and to advance the development of our technologies and product candidates and to extend our cash resources beyond the third quarter of 2026 will remain wholly dependent on our ability to secure collaborations or other transactions for our more advanced clinical-stage programs that provide significant upfront funding in the very near term.”
SEC MD&A · May 14, 2026
ST-503 for SFN has FDA Fast Track Designation and is in Phase 1/2.
“In December 2025, the FDA granted Fast Track Designation to ST-503. Fast Track Designation aims to facilitate the development and expedite the review of new therapeutics that”
SEC MD&A · March 30, 2026
Catalyst timeline
- 2019-03-06 · Phase 1/2 start for BIVV003 (sickle cell disease) — This is a historical catalyst; the company's current focus is on neurology and Fabry programs.
- 2019-07-23 · Phase 1/2 start for ST-920 (Fabry disease) - STAAR study — This registrational study has completed; long-term follow-up is ongoing.
- 2021-03-17 · Phase 1/2a start for CAR Treg therapy in renal transplant — This is a historical catalyst; the company's current focus is on neurology and Fabry programs.
Risks & what to watch (4)›
Key risks
- Imminent cash depletion — Cash runway ends after Q3 2026; no funding secured for operations beyond that point [sec_mda · as of 2026-05-14].
- Negative shareholders' equity — Shareholders' equity is -$19.0M as of 2026-03-31, indicating liabilities exceed assets [sec].
- Dependence on near-term partnerships — Survival hinges on securing collaborations or transactions for advanced programs in the very near term [sec_mda · as of 2026-05-14].
- Stock volatility and delisting risk — Stock price has been volatile; delisting from Nasdaq would impair capital raising ability [sec_mda · as of 2026-03-30].
What to watch
- Whether Sangamo can secure a collaboration or transaction for its Fabry disease program (isaralgagene civaparvovec) to provide upfront funding before Q3 2026 ends [sec_mda · as of 2026-05-14].
- Progress of the rolling BLA submission for isaralgagene civaparvovec, expected as early as summer 2026, and any FDA feedback [sec_mda · as of 2026-05-14].
- Enrollment and initial data from the Phase 1/2 STAND study of ST-503 for SFN, which has Fast Track Designation [sec_mda · as of 2026-03-30].
- Any further cost-reduction measures, headcount reductions, or potential bankruptcy filings [sec_mda · as of 2026-03-30].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run SANGAMO THERAPEUTICS, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SANGAMO THERAPEUTICS, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.3 months
OCF -$19M · Net income -$31M
Lead: Approved
3 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
111
Total value held
$26.0M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 40,400,067 | $10.0M |
| vanguard capital management llc | 12,704,408 | $3.1M |
| two sigma investments, lp | 6,270,441 | $1.5M |
| balyasny asset management l.p. | 5,288,097 | $1.3M |
| geode capital management, llc | 4,570,862 | $1.1M |
| blackrock, inc. | 4,547,848 | $1.1M |
| renaissance technologies llc | 3,836,665 | $947K |
| ubs group ag | 2,570,992 | $635K |
| charles schwab investment management inc | 2,352,360 | $581K |
| vanguard fiduciary trust co | 2,310,297 | $571K |
Showing top 10 of 111 institutional holders of SANGAMO THERAPEUTICS, INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 10.4%
- Days to cover
- 5.5
- Shares short
- 42,883,635
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGMOQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for SANGAMO THERAPEUTICS, INC?
SANGAMO THERAPEUTICS is a genomic medicine company focused on epigenetic regulation therapies for serious neurological diseases, but faces an acute liquidity crisis that threatens its ability to continue operations beyond the third quarter of 2026.
What is SANGAMO THERAPEUTICS, INC's lead drug candidate?
SANGAMO THERAPEUTICS, INC's most advanced tracked candidate is giroctocogene fitelparvovec (Approved) for moderately severe to severe hemophilia A.
Who is the CEO of SANGAMO THERAPEUTICS, INC?
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. is the chief executive officer of SANGAMO THERAPEUTICS, INC (SGMOQ).
Where is SANGAMO THERAPEUTICS, INC headquartered?
SANGAMO THERAPEUTICS, INC (SGMOQ) is headquartered in Richmond, CA, United States.
What therapeutic areas does SANGAMO THERAPEUTICS, INC focus on?
SANGAMO THERAPEUTICS, INC develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Cardiovascular, Pain, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.